Literature DB >> 21521021

Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes.

Huijuan Wang1, Ting Bian, Duan Liu, Tianbo Jin, Yong Chen, Aifen Lin, Chao Chen.   

Abstract

AIM: Tegafur is primarily converted to 5-fluorouracil (5-FU) by CYP2A6 in the human liver to exert its antitumor effect. Our objective was to comprehensively investigate the effects of CYP2A6 genetic polymorphisms on tegafur bioactivation activity. MATERIALS &
METHODS: Using a set of over 45 Chinese livers, the association between CYP2A6 genetic variations and 5-FU formation rates from tegafur, as well as CYP2A6 mRNA and protein levels, was determined.
RESULTS: A total of 20 polymorphic variants and 20 haplotypes of CYP2A6 were identified. From genotype/haplotype-phenotype association tests, we demonstrated that CYP2A6*4 was the main allele responsible for the decreased 5-FU formation from tegafur and CYP2A6 expression in this population. By contrast, haplotype 14 (a novel CYP2A6*1B allele) was associated with increased microsomal 5-FU formation activity and CYP2A6 expression, and this may be attributed to the combined effects of three single variants (g.22C>T, g.1620T>C and a gene conversion in the 3´-UTR) included in this haplotype.
CONCLUSION: We concluded that CYP2A6*4 and the novel CYP2A6*1B variant were the major genetic determinants of interindividual variability in 5-FU formation from tegafur in Chinese livers. Original submitted 2 November 2010; Revision submitted 3 December 2010.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21521021     DOI: 10.2217/pgs.10.202

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  9 in total

Review 1.  Pharmacologic resistance in colorectal cancer: a review.

Authors:  William A Hammond; Abhisek Swaika; Kabir Mody
Journal:  Ther Adv Med Oncol       Date:  2016-01       Impact factor: 8.168

Review 2.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 3.  PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6.

Authors:  Ellen M McDonagh; Catherine Wassenaar; Sean P David; Rachel F Tyndale; Russ B Altman; Michelle Whirl-Carrillo; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2012-09       Impact factor: 2.089

4.  Novel CYP2A6 variants identified in African Americans are associated with slow nicotine metabolism in vitro and in vivo.

Authors:  Mark Piliguian; Andy Z X Zhu; Qian Zhou; Neal L Benowitz; Jasjit S Ahluwalia; Lisa Sanderson Cox; Rachel F Tyndale
Journal:  Pharmacogenet Genomics       Date:  2014-02       Impact factor: 2.089

Review 5.  Variation in CYP2A6 Activity and Personalized Medicine.

Authors:  Julie-Anne Tanner; Rachel F Tyndale
Journal:  J Pers Med       Date:  2017-12-01

Review 6.  Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.

Authors:  Daphne Bertholee; Jan Gerard Maring; André B P van Kuilenburg
Journal:  Clin Pharmacokinet       Date:  2017-04       Impact factor: 6.447

Review 7.  A Systematic Review of Clinical Validated and Potential miRNA Markers Related to the Efficacy of Fluoropyrimidine Drugs.

Authors:  Xiaomeng Sun; Jiani Chen; Xintao Chen; Qianmin Gao; Wei Chen; Xun Zou; Feng Zhang; Shouhong Gao; Shi Qiu; Xiaoqiang Yue; Houshan Yao; Xuan Liu; Mingming Li
Journal:  Dis Markers       Date:  2022-08-23       Impact factor: 3.464

Review 8.  Intratumoural Cytochrome P450 Expression in Breast Cancer: Impact on Standard of Care Treatment and New Efforts to Develop Tumour-Selective Therapies.

Authors:  Smarakan Sneha; Simon C Baker; Andrew Green; Sarah Storr; Radhika Aiyappa; Stewart Martin; Klaus Pors
Journal:  Biomedicines       Date:  2021-03-12

9.  Content and activity of human liver microsomal protein and prediction of individual hepatic clearance in vivo.

Authors:  Haifeng Zhang; Na Gao; Xin Tian; Tingting Liu; Yan Fang; Jun Zhou; Qiang Wen; Binbin Xu; Bing Qi; Jie Gao; Hongmeng Li; Linjing Jia; Hailing Qiao
Journal:  Sci Rep       Date:  2015-12-04       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.